CD274 and gastric cancer: In the estimated 15% to 20% of the GC patients who overexpress claudin 18.2 and present PD-L1 expression CPS ≥ 5, the decision between immunotherapy and zolbetuximab in the first-line setting and the sequencing of the systemic therapy should be made on a case-by-case basis until definitive data are provided by the literature.